Home Cart Sign in  
Chemical Structure| 1628256-23-4 Chemical Structure| 1628256-23-4

Structure of Lerociclib
CAS No.: 1628256-23-4

Chemical Structure| 1628256-23-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

G1T38 is a potent, selective, and orally bioavailable CDK4/6 inhibitor with unique pharmacokinetic and pharmacodynamic properties, which result in high efficacy against CDK4/6 dependent tumors while minimizing the undesirable on-target bone marrow activity.

Synonyms: G1T38

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lerociclib

CAS No. :1628256-23-4
Formula : C26H34N8O
M.W : 474.60
SMILES Code : O=C1NCC2(CCCCC2)N3C1=CC4=CN=C(N=C43)NC5=NC=C(C=C5)N6CCN(CC6)C(C)C
Synonyms :
G1T38
MDL No. :MFCD31692381

Safety of Lerociclib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Lerociclib

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
COA79 cells 0–10 μM 72 hours To evaluate the effect of Lerociclib on the viability of COA79 cells. Results showed that Lerociclib significantly reduced the viability of COA79 cells. J Pediatr Surg. 2024 Mar;59(3):473-482
COA30 cells 0–10 μM 72 hours To evaluate the effect of Lerociclib on the viability of COA30 cells. Results showed that Lerociclib significantly reduced the viability of COA30 cells. J Pediatr Surg. 2024 Mar;59(3):473-482
MG-63 cells 0–10 μM 72 hours To evaluate the effect of Lerociclib on the viability of MG-63 cells. Results showed that Lerociclib significantly reduced the viability of MG-63 cells. J Pediatr Surg. 2024 Mar;59(3):473-482
U-2 OS cells 0–10 μM 72 hours To evaluate the effect of Lerociclib on the viability of U-2 OS cells. Results showed that Lerociclib significantly reduced the viability of U-2 OS cells. J Pediatr Surg. 2024 Mar;59(3):473-482

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Female nu/nu mice MCF7 xenograft model Oral 50 mg/kg (lerociclib), 30 or 100 mg/kg (G1T48) Once daily for 28 days Evaluate the antitumor activity of G1T48 and lerociclib combination therapy in estrogen-dependent breast cancer xenograft models Breast Cancer Res Treat. 2020 Apr;180(3):635-646

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.54mL

2.11mL

1.05mL

21.07mL

4.21mL

2.11mL

References

 

Historical Records

Categories